← SynDRA
SOTORASIB
SynDRA canonical compound SYN0039911 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | KRAS |
|---|
| Mechanism of action | K-Ras inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- K-Ras inhibitor
- KRAS INHIBITOR
Cross-references
Synonyms
- KRAS G12C INHIBITOR 9
- KRAS MUTANT-TARGETING AMG 510
- (R)-38
- (S)-AMG-510
- AMG-510
- AMG510
- CT-AMG510AMG-510AMG510
- Lumakras
- Lumykras
- SOTORASIB (AMG510) RACEMATE
- AMG 510
- AMG-510 racemate
- Kras G12C inhibitor 9
- UNII-2B2VM6UC8G
- 2B2VM6UC8G
- CHEMBL4535757
- 2296729-00-3 (racemate)
- 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one
- 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one
- Sotorasib [INN]
- 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one
- AMG510 racemate
- Sotorasib [USAN]
- AMG-510(racemate)
- Kras mutant-targeting AMG 510
- SCHEMBL20560375
- GTPL10678
- AMG 510 pound>>AMG-510
- AMY16918
- BCP30452
- BCP33368
- EX-A3538
- BDBM50514402
- NSC818433
- s8830
- WHO 11370
- DB15569
- NSC-818433
- BS-16684
Reported adverse events
- Abdominal pain
- Arthralgia
- Aspartate aminotransferase increased
- Conjunctivitis
- Constipation
- Cough
- Dry skin
- Fatigue
- Hepatotoxicity
- Infection
- Musculoskeletal pain
- Nail disorder
Look up SOTORASIB in the interactive SynDRA portal →